Trial
NCT05124561
Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)
Phase IIIWITHDRAWNREGULATORYConfidence: HIGH
Sponsor
CanSino Biologics Inc.
Collaborators
Beijing Institute of Biotechnology
Condition
COVID-19
Intervention
Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
Why stopped
The trial protocol was not approved by the regulatory authorities.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-18